IRIS
ROTI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.897
EU - Europa 2.815
AS - Asia 2.041
SA - Sud America 258
AF - Africa 44
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.063
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.845
SG - Singapore 777
IT - Italia 764
CN - Cina 740
IE - Irlanda 487
SE - Svezia 355
HK - Hong Kong 307
DE - Germania 300
BR - Brasile 237
FI - Finlandia 184
NL - Olanda 163
UA - Ucraina 139
FR - Francia 101
AT - Austria 90
TR - Turchia 89
RU - Federazione Russa 70
GB - Regno Unito 64
IN - India 50
CA - Canada 35
CI - Costa d'Avorio 29
BE - Belgio 24
BD - Bangladesh 18
CZ - Repubblica Ceca 15
PL - Polonia 13
IR - Iran 11
JP - Giappone 11
ID - Indonesia 8
AR - Argentina 7
MX - Messico 7
PK - Pakistan 7
AU - Australia 6
ES - Italia 6
PA - Panama 6
LT - Lituania 5
LU - Lussemburgo 5
RO - Romania 5
CH - Svizzera 4
UY - Uruguay 4
ZA - Sudafrica 4
DZ - Algeria 3
HU - Ungheria 3
IQ - Iraq 3
JM - Giamaica 3
MA - Marocco 3
PH - Filippine 3
RS - Serbia 3
VN - Vietnam 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CO - Colombia 2
EC - Ecuador 2
EG - Egitto 2
GR - Grecia 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
PE - Perù 2
UZ - Uzbekistan 2
VE - Venezuela 2
AL - Albania 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
HR - Croazia 1
JO - Giordania 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MT - Malta 1
NG - Nigeria 1
NP - Nepal 1
NR - Nauru 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 8.063
Salva come PNG Salva come JPEG
Città #
Singapore 503
Dublin 487
Chandler 472
Hong Kong 304
Santa Clara 254
Ashburn 253
Parma 243
Boardman 187
Beijing 145
Jacksonville 135
Ann Arbor 126
Dearborn 105
Princeton 90
Nanjing 84
Munich 77
Vienna 77
Shanghai 76
Izmir 72
Wilmington 62
Helsinki 55
Bologna 53
Grafing 53
San Mateo 50
Shenyang 49
Marseille 48
Jinan 44
Milan 44
Nanchang 42
New York 42
Moscow 39
Hebei 32
Hefei 30
Abidjan 29
Los Angeles 29
Turku 29
Seattle 27
Toronto 25
Verona 24
Kunming 22
Brussels 21
Des Moines 21
Guangzhou 21
Amsterdam 20
Changsha 20
Tianjin 20
Columbus 19
Modena 19
Dallas 18
Nuremberg 18
Bremen 17
Pune 17
Reggio Emilia 17
São Paulo 17
The Dalles 17
Frankfurt am Main 16
Fremont 16
Jiaxing 16
Rome 15
Chicago 14
West Jordan 14
Norwalk 13
Perugia 13
Brno 12
Düsseldorf 12
Houston 11
Rio de Janeiro 11
Woodbridge 11
Hangzhou 10
London 10
Bengaluru 9
Brescia 9
Carpi 9
Chongqing 9
Haikou 9
Trento 9
Zhengzhou 9
Council Bluffs 8
Jakarta 8
Kocaeli 8
Auburn Hills 7
Florence 7
Ningbo 7
Turin 7
Brooklyn 6
Guarulhos 6
Istanbul 6
Malo 6
Phoenix 6
San Francisco 6
Warsaw 6
Atlanta 5
Belo Horizonte 5
Bolzano 5
Charlotte 5
Chengdu 5
Lanzhou 5
Mestre 5
Montreal 5
Naples 5
Trieste 5
Totale 5.201
Salva come PNG Salva come JPEG
Nome #
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 151
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia 144
Targeting oncogenic Notch signaling with SERCA inhibitors 137
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 137
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 115
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 114
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 111
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 110
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 110
Impact of the rs1024611 polymorphism of ccl2 on the pathophysiology and outcome of primary myelofibrosis 109
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 107
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 105
Angiopoietins expression by human myeloma cells 103
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 102
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 101
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 101
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 99
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 97
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 96
227P Sexual dimorphism in immune profile of early and advanced NSCLC 92
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 92
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 91
IL-7 is produced by myeloma cells in presence of IL-6 91
Osteopontin is produced by human multiple myeloma cells 90
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 87
Acute lymphoblastic leukaemia in Noonan syndrome. 86
Multiple myeloma patient with unusual extramedullary involvement 85
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 85
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 83
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL 83
Multiple Myeloma patient with unusual extramedullary involvement 82
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 82
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 82
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 80
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 80
Targeting Notch Trafficking and Processing in Cancers 80
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 78
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 78
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 77
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia 77
Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML 77
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 75
Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis 75
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 75
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia 75
IL-7 is produced by myeloma cells in presence of IL-6 75
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia 75
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 74
Activating somatic and germline TERT promoter variants in myeloid malignancies 74
Multiple myeloma patient with unusual extramedullary involvement 74
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling 74
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia 73
Genetic and proteomic approaches to identify cancer drug targets. 71
Venetoclax and bortezomib in relapsed/refractory early t-cell precursor acute lymphoblastic leukemia 71
Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. 71
Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells 71
THERAPEUTIC TARGETING OF NOTCH SIGNALING PATHWAY IN HEMATOLOGICAL MALIGNANCIES 71
Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia 70
Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia 70
Bone marrow endothelial cells carry BCR/ABL fusion gene from chronic myeloid leukemia patients. 69
Leukemia-specific delivery of mutant NOT CH1 targeted therapy 68
WO/2016/073708 66
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. 63
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 63
Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro 62
Genetic profile of acute lymphoblastic leukemia in a patient with the noonan syndrome 62
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 62
A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome 62
SERCA MODULATION COUNTERACTS GLUCOCORTICOID RESISTANCE IN T-ALL 61
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 61
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 61
Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia 60
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 60
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 60
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 60
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 58
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. 57
e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia 57
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 56
Constitutive phosphorylation of Janus kinase2 in the GL15 glioblastoma derived human cell line 54
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes 54
CAD204520 Targets NOTCH1 PEST Domain Mutations in Lymphoproliferative Disorders 53
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma 52
Acute lymphoblastic leukaemia 51
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. 51
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 51
Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy with Thyroid Carcinoma Cells: Novel Translational Insights 50
DHPLC analysis of NPM1 mutations in adult primary AML. 48
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E 48
Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: From current standards to precision medicine 47
SELECTIVE BLOCKADE OF ONCOGENIC NOTCH1 WITH THE NEW SERCA INHIBITOR CAD204520 45
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 45
Targeting NOTCH1 in hematopoietic malignancy. 45
Genetic pathways in low-and high-grade HCV-related lymphomas are different 44
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. 44
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement 44
T(10;11)(P13;P14-21) PICALM-MLLT10 ACUTE LEUKEMIA: CHARACTERIZATION OF TWO CASES WITH DIFFERENT PHENOTYPIC PRESENTATION 43
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML 43
Modulating Notch1 With Signature-based Small Molecule Library Screening 43
Mutational analisys of JAK2 VAL617PHE in a new series of chronic myelomonocytic leukemia and related atypical myeloproliferative disorders 43
Totale 7.527
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.564
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202046 0 0 0 0 0 0 0 0 0 0 0 46
2020/2021515 16 33 38 20 56 17 34 23 128 47 78 25
2021/2022517 16 16 11 15 7 64 72 55 27 40 32 162
2022/20231.922 219 191 106 124 206 206 32 117 585 7 82 47
2023/2024987 50 64 29 41 85 184 124 80 40 72 72 146
2024/20253.044 90 164 215 235 337 246 145 137 350 251 275 599
Totale 8.231